title: Essential thrombocythemia after treatment of non-Hodgkin's lymphoma.
authors.forename: James Farley Rafael
authors.initials: JF
authors.lastname: Maciel
authors.forename: Maria
authors.initials: M
authors.lastname: de Lourdes Chauffaille
authors.forename: Riguel Jun
authors.initials: RJ
authors.lastname: Inaoka
authors.forename: Gisele Wally Braga
authors.initials: GW
authors.lastname: Colleoni
authors.forename: Mihoko
authors.initials: M
authors.lastname: Yamamoto
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D013920:Thrombocythemia, Essential / Q000139:chemically induced*; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone